Massachusetts Financial Services Co. MA Decreases Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Massachusetts Financial Services Co. MA lessened its holdings in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,564 shares of the biotechnology company’s stock after selling 1,127 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Anika Therapeutics were worth $1,150,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Segall Bryant & Hamill LLC boosted its holdings in shares of Anika Therapeutics by 1.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 108,799 shares of the biotechnology company’s stock worth $2,687,000 after purchasing an additional 1,794 shares during the last quarter. Quest Partners LLC boosted its stake in Anika Therapeutics by 115.8% during the third quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock worth $171,000 after buying an additional 3,705 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new stake in Anika Therapeutics in the 3rd quarter valued at $238,000. Atria Investments Inc acquired a new stake in shares of Anika Therapeutics in the 3rd quarter worth $218,000. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Anika Therapeutics by 7.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 50,745 shares of the biotechnology company’s stock worth $1,253,000 after acquiring an additional 3,733 shares during the period. Institutional investors and hedge funds own 91.53% of the company’s stock.

Anika Therapeutics Stock Performance

NASDAQ ANIK opened at $17.72 on Thursday. The stock has a fifty day simple moving average of $21.77 and a 200-day simple moving average of $24.47. The stock has a market cap of $259.60 million, a PE ratio of -2.66 and a beta of 0.86. Anika Therapeutics, Inc. has a twelve month low of $16.00 and a twelve month high of $29.11.

Analysts Set New Price Targets

Several research firms recently issued reports on ANIK. Barrington Research cut their price objective on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. StockNews.com downgraded shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 4th.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.